Ingenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion

Dermatology. 2016:232 Suppl 1:17-9. doi: 10.1159/000447391. Epub 2016 Aug 11.

Abstract

Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated with physician-directed IM 0.015% gel under occlusion over the chest area.

Publication types

  • Case Reports

MeSH terms

  • Administration, Cutaneous
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage*
  • Bowen's Disease / drug therapy*
  • Bowen's Disease / pathology
  • Diterpenes / administration & dosage*
  • Humans
  • Male
  • Off-Label Use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Thorax

Substances

  • 3-ingenyl angelate
  • Antineoplastic Agents
  • Diterpenes